Intravascular Imaging Incorporated ("I3") Announces Launch Of Its 3-French Nirf-Ivus Imaging Catheter Intended For Human Coronary Imaging, With Favorable Tests In Ex-Vivo Human Coronaries, And Launch Of Series A Financing

I3 today announced the launch of its proprietary 3-French NIRF-IVUS Catheter designed in collaboration with the Massachusetts General Hospital. The device was tested in ex-vivo human coronary arteries and in vivo in preclinical studies, using its proprietary NIRF-IVUS intravascular imaging system. I3's imaging system combines intravascular ultrasound ("IVUS"), the dominant imaging approach used for coronary stent optimization during percutaneous coronary intervention (PCI), with near-infrared fluorescence imaging ("NIRF"). Combined into a single catheter, NIRF-IVUS enables visualization of the molecular and cellular details that underline pathophysiologic progression of coronary lesions, arterial dissections, coronary transplant vasculopathy, and fibrin production in unhealed stents.